Avalo Therapeutics, Inc. AVTX

US Biotechnology

$7.07 ▼ -2.75% ($-0.20)

🔥 High Short Interest

Open $7.12

Prev Close $7.27

Day Range $6.96 – $7.57

52W Range $6.53 – $24.27

Market Cap $420.37M

Beta 0.75

EPS (TTM) $-4.75

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2015-11-13
Shares Out.	53,630,000
Website	avalotx.com/ ↗
Phone	13026365400
Employees	33
Revenue	$0
Gross Profit	$0
Net Income	-$18.9M
Free Cash Flow	-$63.5M
Total Assets	$481.4M
Total Liabilities	$44.9M
Equity	$436.5M

About Avalo Therapeutics, Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Avalo Therapeutics, Inc. is a publicly traded company under the ticker symbol AVTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.